Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Read it at TD Ameritrade, it was an article from Barrons.com:

Resolute Energy's Resolve -- Barrons.com
7:59 pm ET October 26, 2018 (Dow Jones) Print

13Ds are filed with the Securities and Exchange Commission within 10 days of an entity's attaining a greater than 5% position in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material has been extracted from filings released by the SEC from Oct. 18 through Oct. 24, 2018. Source: InsiderScore.com
Activist Filings

Marker Therapeutics (MRKR)
Aisling Capital Partners disclosed its initial ownership of 3,500,000 shares of the immunotherapy biotech company. The holding, the rough equivalent of 7.7% of the outstanding stock, cost $8 million to acquire as part of Marker's $70 million private placement financing, which closed on Oct. 17. The placement was in conjunction with the acquisition of privately held Marker by TapImmune (formerly TPIV) on the same day. TapImmune changed its name to Marker Therapeutics and began trading under the ticker MRKR following the merger's close.